FDA withheld data from advisory committee

The FDA withheld from an advisory committee data linking the anti-obesity drug orlistat to a potential cancer risk before the committee recommended its switch from prescription to OTC status, alleges an article in the Cancer Letter. It said FDA had been aware of the data since 1997.
You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory